B-Cell Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BCL017 MIFTS: 61	B-Cell Lymphoma Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for B-Cell Lymphoma

MalaCards integrated aliases for B-Cell Lymphoma:

Name: B-Cell Lymphoma ¹¹ ¹⁹ ²⁸ ¹⁴ ³⁶ ⁷⁵

Lymphoma, B-Cell ¹⁹ ⁴³ ³⁸

B-Cell Lymphomas ⁷⁵ ¹⁴ ⁷¹

B-Cell Lymphocytic Neoplasm ¹¹

B-Cell Lymphoma Nos ³³

Lymphoma B-Cell ⁵³

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Other and unspecified types of non-Hodgkin lymphoma

B-cell lymphoma, unspecified

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Mature B-cell neoplasms

B-cell lymphoma, mixed features

Malignant lymphoma of B cell type, not elsewhere classified

External Ids:

Disease Ontology ¹¹ DOID:707

MeSH ⁴³ D016393

NCIt ⁴⁹ C3457

SNOMED-CT ⁶⁸ 109979007

ICD10 ³¹ C85.1

ICD11 ³³ 1275688866

UMLS ⁷¹ C0079731

Sources

Summaries for B-Cell Lymphoma

GARD: ¹⁹ "B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the ""B-cells"" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders."

MalaCards based summary: B-Cell Lymphoma, also known as lymphoma, b-cell, is related to marginal zone b-cell lymphoma and lymphoma, mucosa-associated lymphoid type. An important gene associated with B-Cell Lymphoma is MIR17 (MicroRNA 17), and among its related pathways/superpathways are Cytokine Signaling in Immune system and NF-kappaB Signaling. The drugs Lomustine and Rivoceranib have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone marrow, and related phenotypes are endocrine/exocrine gland and cellular

Disease Ontology: ¹¹ A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia ⁷⁵ B-cell lymphoma: The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are "blood cancers" in the lymph... more...

B-cell lymphomas: Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood... more...

Sources

Related Diseases for B-Cell Lymphoma

Diseases in the B-Cell Lymphoma family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1586)

#	Related Disease	Score	Top Affiliating Genes
1	marginal zone b-cell lymphoma	33.9	MYC MALT1 IRF4 CCND1 BCL6 BCL2
2	lymphoma, mucosa-associated lymphoid type	33.8	MYC MALT1 IRF4 CCND1 BCL6 BCL2
3	diffuse large b-cell lymphoma	33.7	PRDM1 MYC MIR17 IRF4 HOTAIR BCL6
4	primary mediastinal b-cell lymphoma	33.6	MYC IRF4 BCL6 BCL2
5	intravascular large b-cell lymphoma	33.5	BCL6 BCL2
6	high-grade b-cell lymphoma double-hit/triple-hit	33.5	MYC IRF4 BCL6 BCL2
7	relapsed/refractory diffuse large b-cell lymphoma	33.4	MYC BCL6 BCL2
8	diffuse large b-cell lymphoma activated b-cell type	33.3	MYC IRF4 BCL6 BCL2
9	nodal marginal zone lymphoma	33.2	MALT1 IRF4 BCL6 BCL2 BCL10
10	plasmablastic lymphoma	33.2	PRDM1 MYC IRF4 BCL6
11	lymphoma	33.2	PVT1 PRDM1 MYC MCL1 MALT1 IRF4
12	follicular lymphoma	33.1	MYC MCL1 IRF4 CCND1 BCL6 BCL2L1
13	gray zone lymphoma	33.1	IRF4 BCL6
14	lymphoma aids related	32.9	MYC BCL6
15	splenic marginal zone lymphoma	32.9	MALT1 CCND1 BCL6
16	chronic lymphocytic leukemia/small lymphocytic lymphoma	32.8	CCND1 BCL6 BCL2
17	reticulosarcoma	32.8	MYC BCL6 BCL2
18	burkitt lymphoma	32.7	TP53COR1 PVT1 PRDM1 MYC IRF4 BCL6
19	lymphoma, hodgkin, classic	32.7	PVT1 MIR20A MCL1 IRF4 BCL6 BCL3
20	monoclonal gammopathy of uncertain significance	32.6	MYC IRF4 CCND1
21	lymphoma, non-hodgkin, familial	32.5	MYC MIR20A MIR17 MCL1 MALT1 IRF4
22	b-cell non-hodgkin lymphoma	32.2	PRDM1 BCL6
23	central nervous system lymphoma	32.2	MYC IRF4 BCL6 BCL2
24	gastric lymphoma	32.2	MALT1 IRF4 BCL6 BCL2 BCL10
25	breast lymphoma	32.0	IRF4 BCL6 BCL2
26	acquired immunodeficiency syndrome	31.9	MYC CCND1 BCL6 BCL2
27	lymphoplasmacytic lymphoma	31.9	IRF4 CCND1 BCL6 BCL2
28	leukemia, acute lymphoblastic	31.9	MYC MIR17 MCL1 IRF4 BCL6 BCL2L1
29	anaplastic large cell lymphoma	31.9	MCL1 BCL3 BCL2L1 BCL2
30	testicular lymphoma	31.9	IRF4 BCL6 BCL2
31	richter's syndrome	31.9	MYC BCL6 BCL2
32	peripheral t-cell lymphoma	31.9	MIR17 MCL1 BCL6 BCL3 BCL2
33	bone lymphoma	31.8	IRF4 BCL6 BCL2
34	leukemia, chronic lymphocytic 2	31.8	MCL1 BCL3 BCL2
35	mantle cell lymphoma	31.7	MYC MIR17 MCL1 MALT1 MALAT1 IRF4
36	lung lymphoma	31.7	MALT1 IRF4 BCL6
37	gastrointestinal lymphoma	31.7	MALT1 CCND1 BCL6 BCL2 BCL10
38	peripheral nervous system disease	31.6	MYC MIR17 MCL1 CCND1 BCL2L1 BCL2
39	composite lymphoma	31.6	BCL6 BCL2
40	leukemia	31.6	MYC MCL1 HOTAIR GAS5 CCND1 BCL3
41	t-cell acute lymphoblastic leukemia	31.5	MYC MIR17 IRF4 GAS5 BCL2L1 BCL2
42	adult lymphoma	31.5	PRDM1 MYC IRF4 BCL6 BCL2
43	adult t-cell leukemia/lymphoma	31.5	MYC IRF4 BCL2
44	colon lymphoma	31.5	CCND1 BCL6 BCL2
45	leukemia, chronic lymphocytic	31.4	TP53COR1 MYC MIR20A MIR17 MCL1 IRF4
46	orofaciodigital syndrome viii	31.4	MALT1 BCL6 BCL10
47	hematologic cancer	31.4	PVT1 MIR20A MIR17 IRF4 BCL2
48	colonic benign neoplasm	31.3	MYC CCND1 BCL2L1 BCL2
49	orbit lymphoma	31.3	MALT1 BCL10
50	plasmacytoma	31.3	PVT1 PRDM1 MYC IRF4 GAS5 CCND1

Graphical network of the top 20 diseases related to B-Cell Lymphoma:

Sources

Symptoms & Phenotypes for B-Cell Lymphoma

MGI Mouse Phenotypes related to B-Cell Lymphoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	9.96	BCL10 BCL11A BCL2 BCL2L1 BCL6 CCND1
2	cellular	MP:0005384	9.93	BCL10 BCL11A BCL2 BCL2L1 BCL6 CCND1
3	no phenotypic analysis	MP:0003012	9.87	BCL6 HOTAIR MALAT1 MYC PRDM1 TP53COR1
4	immune system	MP:0005387	9.77	BCL10 BCL11A BCL2 BCL2L1 BCL3 BCL6
5	hematopoietic system	MP:0005397	9.4	BCL10 BCL11A BCL2 BCL2L1 BCL3 BCL6

Sources

Drugs & Therapeutics for B-Cell Lymphoma

Drugs for B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 419)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lomustine

Approved, Investigational

Phase 4

13010-47-4

3950

Rivoceranib

Investigational

Phase 4

811803-05-1

11315474

Endothelial Growth Factors

Phase 4

Lamivudine

Approved, Investigational

Phase 2, Phase 3

134678-17-4

60825

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Carmustine

Approved, Investigational

Phase 3

154-93-8

2578

Blinatumomab

Approved, Investigational

Phase 2, Phase 3

853426-35-4

Pixantrone

Approved, Investigational

Phase 3

144510-96-3

134019

Darbepoetin alfa

Approved, Investigational

Phase 3

209810-58-2

Chlorambucil

Approved

Phase 3

305-03-3

2708

Zanubrutinib

Approved, Investigational

Phase 3

1691249-45-2

135565884

Vidarabine

Approved, Investigational

Phase 3

24356-66-9

21704

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Decitabine

Approved, Investigational

Phase 3

2353-33-5

451668

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Thalidomide

Approved, Investigational, Withdrawn

Phase 3

50-35-1

5426

Entecavir

Approved, Investigational

Phase 3

142217-69-4

153941

Cytarabine

Approved, Investigational

Phase 2, Phase 3

147-94-4

6253

Mechlorethamine

Approved, Investigational

Phase 2, Phase 3

51-75-2

4033

Levoleucovorin

Approved, Experimental, Investigational

Phase 2, Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 2, Phase 3

1959-05-2, 59-05-2

4112 126941

Rasburicase

Approved, Investigational

Phase 2, Phase 3

134774-45-1

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Etoposide

Approved

Phase 3

33419-42-0

36462

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Vindesine

Approved, Investigational

Phase 3

59917-39-4, 53643-48-4

40839

Avelumab

Approved, Investigational

Phase 3

1537032-82-8

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Ofatumumab

Approved

Phase 3

679818-59-8

Idarubicin

Approved

Phase 3

58957-92-9

42890

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

59-30-3

6037

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 3

67-97-0, 1406-16-2

5280795 10883523

Arginine

Approved, Investigational, Nutraceutical

Phase 3

74-79-3

6322

Buformin

Investigational, Withdrawn

Phase 2, Phase 3

692-13-7

2468

Tenofovir

Experimental, Investigational

Phase 3

147127-20-6, 202138-50-9

464205 6398764

Cortisone

Experimental

Phase 2, Phase 3

53-06-5

222786

Palifosfamide

Investigational

Phase 3

31645-39-3

100427

Prednisolone hemisuccinate

Experimental

Phase 3

2920-86-7

4897

Hypoglycemic Agents

Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 1807)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma	Unknown status	NCT01949818	Phase 4	Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2	Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma	Unknown status	NCT03513601	Phase 4	(R)-CHOP regimen;(R)-CVP regimen
3	A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma	Unknown status	NCT03579082	Phase 4	Decitabine
4	Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma	Unknown status	NCT04152577	Phase 4	R2-combination chemotherapy;R-combination chemotherapy
5	Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial	Unknown status	NCT02992834	Phase 4
6	LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)	Completed	NCT00466258	Phase 4	R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
7	Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study	Completed	NCT03376958	Phase 4	Apatinib
8	B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021)	Recruiting	NCT05518383	Phase 4	Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
9	Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma.	Active, not recruiting	NCT02752815	Phase 4	Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
10	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.	Enrolling by invitation	NCT03229200	Phase 4	Ibrutinib
11	A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients	Unknown status	NCT02772822	Phase 3	SCT400 plus CHOP;Rituximab plus CHOP
12	Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma	Unknown status	NCT02767674	Phase 3	Rituximab;Gemcitabine;Oxaliplatin;Cyclophosphamide;Epirubicin Injectable Product;Vindesine;Prednisone
13	R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail	Unknown status	NCT00846157	Phase 3
14	A Phase III, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of SIBP-02 (Rituximab Biosimilar) and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL	Unknown status	NCT04361279	Phase 3	SIBP-02;Rituximab
15	Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)	Unknown status	NCT03777085	Phase 3	TQB2303;Rituximab
16	A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells.	Unknown status	NCT00499018	Phase 3	Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;VP-16
17	A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B	Unknown status	NCT01852435	Phase 3	R-CEOP-70;R-CEOP-90;R-CHOP-50
18	Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study	Unknown status	NCT02777736	Phase 3	Methotrexate
19	CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma	Unknown status	NCT03391726	Phase 2, Phase 3
20	A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT，in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL	Unknown status	NCT03213977	Phase 3	R-DA-EPOCH;R-DA-EPOCH + auto-HSCT;R-CEOP90;R-CEOP90 + auto-HSCT
21	A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma	Unknown status	NCT03151044	Phase 3	High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
22	Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation	Unknown status	NCT03229616	Phase 2, Phase 3	Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
23	A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated Diffuse Large B-cell Lymphoma (DLBCL) Patients	Unknown status	NCT03650933	Phase 3
24	High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial	Unknown status	NCT02531841	Phase 3	Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
25	Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients	Unknown status	NCT01277172	Phase 2, Phase 3
26	Cinobufacini Tablets Combined With R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone)/CHOP in Treatment of Diffuse Large B Cell Lymphoma: A Phase II Randomized, Controlled and Multi-center Study	Unknown status	NCT02871869	Phase 2, Phase 3	vindesine;cyclophosphamide;Epirubicin;prednisone tablets;Cinobufacini Tablets;Rituximab
27	Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma	Unknown status	NCT03018626	Phase 3	Rituximab;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide;Prednisone;Vindesine;Bleomycin
28	An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients	Unknown status	NCT03318835	Phase 3	Thalidomide combined with R-CHOP;R-CHOP
29	Prospective, Multicenter, Randomized ,Open-labeled, Phase III Study Comparing High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for the Prophylaxis of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma	Unknown status	NCT03123718	Phase 3	Intrathecal methotrexate;High-dose intravenous methotrexate
30	Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study	Unknown status	NCT02428751	Phase 3	Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
31	Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy	Unknown status	NCT01156259	Phase 3
32	Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study	Unknown status	NCT01210287	Phase 2, Phase 3	nucleoside analog reverse transcriptase inhibitor
33	Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	Unknown status	NCT02991638	Phase 3	Ibrutinib
34	Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial	Unknown status	NCT01516580	Phase 3	Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
35	Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions	Unknown status	NCT02867553	Phase 3	rituximab
36	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
37	Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.	Completed	NCT01805557	Phase 2, Phase 3	R-DHAP;BR-DHAP
38	Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association	Completed	NCT02128061	Phase 3	Lenalidomide;Rituximab
39	Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma	Completed	NCT02617485	Phase 3	Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
40	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.	Completed	NCT04236141	Phase 3	Polatuzumab Vedotin;Bendamustine;Rituximab;Placebo
41	A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line	Completed	NCT02268045	Phase 3
42	A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy	Completed	NCT00790036	Phase 3	Everolimus;Everolimus Placebo
43	A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13	Completed	NCT00400478	Phase 3	Rituximab
44	A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™	Completed	NCT03263026	Phase 3	Enzastaurin Hydrochloride
45	Treatment of Mature B-cell Lymphoma/Leukaemia A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study	Completed	NCT00162656	Phase 3	half cyclophosphamide;without COPADM3;mini CYVE, without 3 maintenance courses;LMB B;LMB C
46	A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
47	Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line	Completed	NCT01122472	Phase 3	Lenalidomide;Placebo
48	Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas	Completed	NCT00355199	Phase 3	Rituximab-HDS;Rituximab-CHOP
49	Improving Sleep Quality, Psychosocial Functioning, and Cancer Related Fatigue With Light Therapy	Completed	NCT03242902	Phase 3
50	Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas	Completed	NCT00118209	Phase 3	cyclophosphamide;doxorubicin;vincristine;prednisone;etoposide;filgrastim;pegfilgrastim

Search NIH Clinical Center for B-Cell Lymphoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

ibritumomab tiuxetan

Ibrutinib

rituximab

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about B-Cell Lymphoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for B-Cell Lymphoma:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to B-Cell Lymphoma:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: lymphoma, b-cell

Sources

Genetic Tests for B-Cell Lymphoma

Genetic tests related to B-Cell Lymphoma:

#	Genetic test	Affiliating Genes
1	B-Cell Lymphoma ²⁸

Sources

Anatomical Context for B-Cell Lymphoma

Organs/tissues related to B-Cell Lymphoma:

MalaCards : T Cells, B Cells, Bone Marrow, Nk Cells, Bone, Myeloid, Breast

Sources

Publications for B-Cell Lymphoma

Articles related to B-Cell Lymphoma:

(show top 50) (show all 35255)

#	Title	Authors	PMID	Year
1	MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. ⁶² ⁴⁶	Inomata M...Sawada K	18941111	2009
2	Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. ⁵³ ⁶²	Bousserouel S...Raul F	20428773	2010
3	Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. ⁵³ ⁶²	Ruzinova MB...Rodig SJ	20442643	2010
4	IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type. ⁵³ ⁶²	Pham-Ledard A...Merlio JP	20054341	2010
5	Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. ⁵³ ⁶²	Riihijarvi S...Leppa S	20190733	2010
6	Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. ⁵³ ⁶²	Wang E...Datto M	20331331	2010
7	Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. ⁵³ ⁶²	Cho HJ...Kong SY	20303013	2010
8	Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. ⁵³ ⁶²	Seki R...Okamura T	19889619	2010
9	Xeroderma pigmentosum skin: an immune privilege site for tumor development. ⁵³ ⁶²	Abid K...Hamzaoui K	19719835	2010
10	The expression of Bcl-2 by proliferating cells varies in different categories of B-cell lymphoma. ⁵³ ⁶²	Masir N...Mason DY	20459572	2010
11	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. ⁵³ ⁶²	Friedberg JW...Shipp MA	19965662	2010
12	Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. ⁵³ ⁶²	Borthakur A...Dudeja PK	19714753	2010
13	Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. ⁵³ ⁶²	Troutaud D...Bordessoule D	20371444	2010
14	Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. ⁵³ ⁶²	Winter JN...Gascoyne RD	20371683	2010
15	Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. ⁵³ ⁶²	Loomis K...Puri A	20122924	2010
16	CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation. ⁵³ ⁶²	Hu XT...Srivastava G	20093404	2010
17	Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. ⁵³ ⁶²	Hunt KE...Reichard KK	18815567	2010
18	An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. ⁵³ ⁶²	Zapata M...Li S	20490333	2010
19	Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. ⁵³ ⁶²	Anastasiadou E...Trivedi P	19966860	2010
20	Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. ⁵³ ⁶²	Metcalf RA...Natkunam Y	20062012	2010
21	Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. ⁵³ ⁶²	Chen Y...Fu K	20093241	2010
22	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. ⁵³ ⁶²	Morin RD...Marra MA	20081860	2010
23	CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. ⁵³ ⁶²	Luo RF...Natkunam Y	20004001	2010
24	Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. ⁵³ ⁶²	Gumina MR...Chiles TC	20107311	2010
25	Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes. ⁵³ ⁶²	Saad AA...Alloub AI	20174727	2010
26	Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma. ⁵³ ⁶²	Gilmore TD...Faber AC	20130454	2010
27	Deregulation of H3K27 methylation in cancer. ⁵³ ⁶²	Martinez-Garcia E...Licht JD	20104248	2010
28	Mechanisms of chromosomal rearrangement in the human genome. ⁵³ ⁶²	Tsai AG...Lieber MR	20158866	2010
29	Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. ⁵³ ⁶²	Forshell TP...Nilsson JA	20103729	2010
30	Cancer chemoprevention locks onto a new polyamine metabolic target. ⁵³ ⁶²	Gerner EW	20103728	2010
31	[Correlation of Bcl-2 with immunological subtype and prognosis in diffuse large B-cell lymphoma.]. ⁵³ ⁶²	Xi YF...Sun RF	20302777	2010
32	Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. ⁵³ ⁶²	Nagel S...Tzankov A	19857547	2010
33	Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. ⁵³ ⁶²	Schwickart M...Dixit VM	20023629	2010
34	Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. ⁵³ ⁶²	Sarosiek KA...Lossos IS	19965678	2010
35	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. ⁵³ ⁶²	Davis RE...Staudt LM	20054396	2010
36	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. ⁵³ ⁶²	Shustik J...Steidl C	19797725	2010
37	Blimp-1 is a tumor suppressor gene in lymphoid malignancies. ⁵³ ⁶²	Hangaishi A...Kurokawa M	20047096	2010
38	Long-range oncogenic activation of Igh-c-myc translocations by the Igh 3' regulatory region. ⁵³ ⁶²	Gostissa M...Alt FW	20010689	2009
39	REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. ⁵³ ⁶²	Wang H...Zhao S	19289490	2009
40	Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. ⁵³ ⁶²	Garcia V...Provencio M	20016842	2009
41	Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? ⁵³ ⁶²	Lee GW...Lee JS	19860620	2009
42	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. ⁵³ ⁶²	Juszczynski P...Shipp MA	19855081	2009
43	[Construction of expression plasmid for fused idiotypic DNA vaccine of B-cell lymphoma]. ⁵³ ⁶²	Wang FX...Dong ZR	20030925	2009
44	Gene expression profiling of diffuse large B-cell lymphoma -- comparison depending on the CD21 antigen expression. ⁵³ ⁶²	MIYAZAKI K	20009432	2009
45	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. ⁵³ ⁶²	Wilkinson ST...Rimsza LM	19814686	2009
46	Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells. ⁵³ ⁶²	Chiu TH...Chung JG	20032398	2009
47	[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. ⁵³ ⁶²	Shui RH...Zhu XZ	20079013	2009
48	[Clinicopathologic and immunohistochemical study of intra-abdominal non-Hodgkin B-cell lymphoma occurring in children]. ⁵³ ⁶²	Yang WP...Huang H	20079016	2009
49	Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. ⁵³ ⁶²	Mottok A...Brauninger A	19734449	2009
50	Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells. ⁵³ ⁶²	Arseneau JR...Ouellette RJ	19725825	2009

Sources

Genes for B-Cell Lymphoma

Genes related to B-Cell Lymphoma (2 elite genes):

(show top 50) (show all 125)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR17	MicroRNA 17	RNA Gene	369.48	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	18941111
2	MIR20A	MicroRNA 20a	RNA Gene	360.04	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18941111
3	GAS5	Growth Arrest Specific 5	RNA Gene	163.13	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	24583225
4	PVT1	Pvt1 Oncogene	RNA Gene	157.58	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	23547836
5	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	156.23	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24583225 27122348
6	TUG1	Taurine Up-Regulated 1	Protein Coding	155.65	Experimental evidence: Locus ³⁷ DISEASES inferred ¹⁴	24583225 27339553
7	TP53COR1	Tumor Protein P53 Pathway Corepressor 1	RNA Gene	155.44	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26475621
8	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	154.32	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	21489289 24583225
9	BCL6	BCL6 Transcription Repressor	Protein Coding	71.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Gene name Proteins Pathways & Interactions (show sections)	19797725 18925696 9283593 (more) 7742550 10843287 18406879 17889713 11567225 12881702 11039912 12775568 12827616 9422982 19525926 16778825 12835729 11943722 10414499 18245479 9401082 14654791 19031715 18165800 17635238 14674895 12405909 12173331 18189332 11743658 10753856 18925695 20079013 10564588 11023530 16185497 15191563 12430874 8555467 18212045 12185781 11697627 9649500 9209651 8618933 7587061 19524106 19052359 18426731 15488654 15370207 15202519 12580956 10637510 9632807 20160358 19786664 12191569 19855081 17625604 15701085 15239399 15024721 14551142 12389616 9746758 8758205 17175379 16046671 15136235 14979479 11972514 10707776 10406897 19307668 18451163 17786713 17545502 17038524 16918993 16867873 16585013 11821949 11688462 11395550 10936424 7795234 20331331 20016842 19701248 18452090 17122510 16249468 15377470 15832092 12562237 12507907 12378521 18645192 18346918
10	BCL10	BCL10 Immune Signaling Adaptor	Protein Coding	54.69	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Gene name Proteins (show sections)	16784987 17167822 16440771 (more) 18346354 16310461 17502353 16177990 10886211 16545185 10665648 18628489 16123224 11493332
11	BCL3	BCL3 Transcription Coactivator	Protein Coding	50.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Gene name Proteins (show sections)	15105810 11672772 18052923 (more) 16384933
12	BCL2	BCL2 Apoptosis Regulator	Protein Coding	49.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Domains & Families (show sections)	18925696 20459572 8639245 (more) 9242549 1951637 8106752 18367485 19234720 17404107 8685041 16799207 19499887 1581586 2208029 9626207 8252486 20302777 19537891 16418494 11567031 10350331 15832092 11697626 11395550 11298531 11113864 9422982 8958800 15880597 10414499 8683246 7734714 8492222 18925695 18165800 17852408 12405909 9758366 9587934 7892160 8297731 1899539 19276283 8774139 20079013 8700536 9192822 9521469 9787151 19514561 19719835 19508293 15503680 15242877 15215171 12402391 11697627 8721444 8523072 2250705 18287131 17892411 17593082 16690525 16547596 15363034 14726400 12749011 12531792 12720479 12580956 12353944 11830458 11778965 11271628 9754175 8653686 1419624 7798385 8144140 2249841 2114553 20428773 19558920 17493380 18801075 18371146 17926189 17038524 16408039 15764395 15690646 14758801 12899209 12826880 1495993 20160358 20093241 19786664
13	CCND1	Cyclin D1	Protein Coding	45.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Gene name (show sections)	18343791 7540362 14654791 (more) 7918073 8492222 8062825 12430874 12647795 16540722 8740788 8774476 1757070 17316759 11816473 9546285 2249841 19321861 14997743 10733493 9209653 7531681 7518196 18716166 8704183 20158866 18438428 11260626 9376597 8573535 19704069 11229304 9831200 8619427 20062012 18838919 15239399 9556424 11697627 8764748 8523072 20490333 20511144 20107311
14	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	37.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	12594230 20442643 8062825 (more) 11182042 20016842 17701581 19638549 15940261 18460403 18754028 11896625 19351371 10658480 18981293 10449032 11697627 19965678 19786664 18287131 17230227 16690525 15832092 12562237 9560795 1321271 16508012 15944707 12417606 9433379 8197157 1493447 2403854 20010689 17175379 10761452 9364867 8934531 19704118 17368758 14979479 9558363 15239399 9546285 1485535 2056771 20079016 19857547 20079013 18493992 10910917 19596258 18426731 15191563 15735016
15	MALT1	MALT1 Paracaspase	Protein Coding	35.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	18367485 14652825 11066071 (more) 15377491 16804917 15191563 15598810 16784987 17519619 16123224 18234275 19714753 16917511 19394813 10760689 10523859 19897720 10979968 16498450
16	PRDM1	PR/SET Domain 1	Protein Coding	32.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	17213024 16585013 19380033 (more) 18596541 16778825 20047096
17	IRF4	Interferon Regulatory Factor 4	Protein Coding	31.84	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15710572 15959530 20174727 (more) 17149956 18987657 14556665 15905193 20054341 18815567 10706878
18	BCL11A	BCL11 Transcription Factor A	Protein Coding	31.68	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Proteins (show sections)
19	MCL1	MCL1 Apoptosis Regulator, BCL2 Family Member	Protein Coding	31.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Domains & Families (show sections)	15343511 15122313 20511144 (more) 12210808 17404107 19234720 17353899 20023629 11389033 12689928
20	BCL2L1	BCL2 Like 1	Protein Coding	31.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Domains & Families (show sections)	12210808 15073604 18371146 (more) 10620629 17283164 10537354 16896168 17353899 19234720 19820387
21	BCL11B	BCL11 Transcription Factor B	Protein Coding	31.25	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Proteins (show sections)
22	REL	REL Proto-Oncogene, NF-KB Subunit	Protein Coding	30.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	17072339 16027730 17197926 (more) 15644776 14755244 18245482 15870177
23	PASD1	PAS Domain Containing Repressor 1	Protein Coding	30.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries Expressions (show sections)
24	PARP9	Poly(ADP-Ribose) Polymerase Family Member 9	Protein Coding	30.09	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Functions (show sections)
25	MDM2	MDM2 Proto-Oncogene	Protein Coding	27.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	12383214 9546285
26	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	27.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	11389032 20104248 20081860
27	BAD	BCL2 Associated Agonist Of Cell Death	Protein Coding	26.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	16646081 20371444 18371146
28	CDK4	Cyclin Dependent Kinase 4	Protein Coding	25.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	9546285 16704435
29	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	25.67	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
30	CD274	CD274 Molecule	Protein Coding	25.66	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
31	MAPK3	Mitogen-Activated Protein Kinase 3	Protein Coding	25.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	19407332
32	PAX5	Paired Box 5	Protein Coding	25.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19725825 16049306 9694719 (more) 15832095 16938666 12609061 16778825 16185503 12360049 9808580 10556196 17717432 18643853 14690578 17476282
33	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	25.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10757332 9777980 10908157
34	MME	Membrane Metalloendopeptidase	Protein Coding	25.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9625422 16705242 14500390 (more) 17430665 10102615 11293907 11493332
35	TP53	Tumor Protein P53	Protein Coding	25.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9262496 12911661 1375111 (more) 8220152 12176791 18165800 10934953 8980251 8107196 12383214 18974112 18559976 17982487 8297731 17881637 15902285 8683246 7833007 11438467 18706692 15533223 7773162 16532027 9665478 10354143 20160358 16690525 16115229 15832092 15363034 14559832 12749011 12562237 12397782 17693666 12940773 10846825 8958800 20371683 19562614 19669207 17695524 17050200 17927592 15168595 12405909 11706071 10761452 10402527 10200002 10194125 7718450 18669630 15085385 8623759 18417679 10913669 10766396 9586912 9546285 19558920 18451163 15370252 15073604 14603341 12899209 12810261 11778965 9839505 10079376 18616513 17609875 7661603 10449032 10096585 12647795
36	CD5	CD5 Molecule	Protein Coding	25.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9796727 8561085 19279536 (more) 8724541
37	FOXP1	Forkhead Box P1	Protein Coding	24.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15944719 18077790 16252263 (more) 15709173 20174727
38	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	24.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17509395 18220322 10886208 (more) 12750159 16440742 15492998 16640812 19734424 12920229 18755494 17134546 15852431 17325487 14569815 12763927 19636007 15690647 19275511 14576483
39	MS4A1	Membrane Spanning 4-Domains A1	Protein Coding	24.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19211644 17675267 19246561 (more) 19276251 12411587 17430665
40	IL4I1	Interleukin 4 Induced 1	Protein Coding	24.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Expressions (show sections)	17356132 12446450
41	NPM1	Nucleophosmin 1	Protein Coding	24.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	9886332
42	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	24.11	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
43	KMT2D	Lysine Methyltransferase 2D	Protein Coding	23.32	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
44	BCL2L2	BCL2 Like 2	Protein Coding	23.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Domains & Families (show sections)
45	TRAF6	TNF Receptor Associated Factor 6	Protein Coding	23.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications localization (show sections)
46	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	23.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15073604 10209486 12609832 (more) 19719835 9712423 10620629 17693666 10537354 19289490 10766396 20428773 12210808 12749011
47	TCL1A	TCL1 Family AKT Coactivator A	Protein Coding	22.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16978196 19966860 10786666 (more) 20079013 19717643 17260020 15586235 12920316
48	AICDA	Activation Induced Cytidine Deaminase	Protein Coding	22.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12511417 17560277 15385936 (more) 16541139 15842661 20158866 18776814 15940261 16882707 12873980 17638864
49	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	22.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18510703 18628489
50	GCSAM	Germinal Center Associated Signaling And Motility	Protein Coding	22.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)

Sources

Variations for B-Cell Lymphoma

Sources

Expression for B-Cell Lymphoma

Search GEO for disease gene expression data for B-Cell Lymphoma.

Sources

Pathways for B-Cell Lymphoma

Pathways related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 33)

#	Super pathways	Score	Top Affiliating Genes
1	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.22	MYC MCL1 IRF4 CCND1 BCL6 BCL2L1
2	NF-kappaB Signaling ³	12.46	BCL10 BCL6 IRF4 MALT1 PRDM1
3	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.13	MYC CCND1 BCL2L1 BCL2
4	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.04	MALT1 CCND1 BCL2L1 BCL10
5	Vitamin D receptor pathway ⁷⁴	12.03	PRDM1 MYC IRF4 CCND1 BCL6
6	Immune response Antigen presentation by MHC class II ²² Show member pathways G-protein signaling N-RAS regulation pathway ²² IL-22 Pathway ⁶⁴ Immune response IL-22 signaling pathway ²²	12.01	MYC MCL1 BCL2L1 BCL2
7	Apoptosis and Autophagy ³ Show member pathways Activation and oligomerization of BAK protein ⁶⁶ AIF Pathway ⁶⁴ Nanomaterial induced apoptosis ⁷⁴ Pro-survival signaling of neuroprotectin D1 ⁷⁴ vRNA Synthesis ⁶⁶	11.99	MYC MCL1 MALT1 BCL2L1 BCL2 BCL10
8	Direct p53 effectors ⁶¹	11.93	PRDM1 MCL1 BCL6 BCL2
9	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	11.9	MYC BCL2L1 BCL2
10	Gastrin signaling pathway ⁷⁴	11.88	MYC CCND1 BCL2L1
11	DNA damage response (only ATM dependent) ⁷⁴	11.77	MYC CCND1 BCL6 BCL2
12	Notch Signaling Pathways ⁶⁵	11.73	MYC CCND1 BCL6 BCL2
13	C-MYB transcription factor network ⁶¹	11.72	MYC CCND1 BCL2
14	Small cell lung cancer ⁷⁴	11.69	BCL2 BCL2L1 CCND1 MYC
15	Acute viral myocarditis ⁷⁴	11.68	CCND1 BCL2L1 BCL2
16	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.66	PRDM1 IRF4 BCL6
17	BCR signaling pathway ⁶¹	11.61	MALT1 BCL6 BCL10
18	Validated targets of C-MYC transcriptional repression ⁶¹	11.58	BCL2 CCND1 MYC
19	IL4-mediated signaling events ⁶¹	11.56	IRF4 BCL6 BCL2L1
20	ATF-2 transcription factor network ⁶¹	11.52	CCND1 BCL2L1 BCL2
21	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.5	MYC CCND1 BCL2L1
22	miRNAs involved in DNA damage response ⁷⁴	11.45	MYC MIR20A MIR17 CCND1
23	IL6-mediated signaling events ⁶¹	11.41	MYC MCL1 BCL2L1
24	Busulfan Pathway, Pharmacodynamics ⁶⁰ Show member pathways Catalytic cycle of mammalian flavin-containing monooxygenases (FMOs) ⁷⁴ Defective FMO3 causes TMAU ⁶⁶ FMO oxidises nucleophiles ⁶⁶	11.4	MYC BCL2L1 BCL2
25	Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins ²²	11.32	MCL1 BCL2L1 BCL2
26	IL-10 Pathway ⁶⁴	11.26	MYC CCND1 BCL2L1
27	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.2	MYC MCL1 IRF4 CCND1 BCL6 BCL2L1
28	Prion disease pathway ⁷⁴	11.19	IRF4 BCL2 BCL11A
29	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) ⁷⁴	11.18	MYC CCND1 BCL2L1
30	Mammary gland development pathway - Embryonic development (Stage 1 of 4) ⁷⁴	10.91	MYC CCND1
31	Mammary gland development pathway - Puberty (Stage 2 of 4) ⁷⁴	10.76	MYC CCND1
32	Regulation of apoptosis by parathyroid hormone-related protein ⁷⁴	10.6	MYC MCL1 BCL2L1 BCL2
33	IL-7 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways B-Cell Development ⁶⁴	10.34	MCL1 BCL2L1 BCL2

Sources

GO Terms for B-Cell Lymphoma

Cellular components related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	Bcl-2 family protein complex	GO:0097136	9.46	MCL1 BCL2L1
2	CBM complex	GO:0032449	9.26	MALT1 BCL10
3	polkadots	GO:0002096	8.92	MALT1 BCL10

Biological processes related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.07	BCL2 BCL2L1 BCL3 BCL6 MALT1 MCL1
2	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	10.04	MCL1 BCL2L1 BCL2
3	response to cytokine	GO:0034097	10.02	MCL1 BCL2L1 BCL2
4	positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0043280	10.01	BCL10 MALT1 MYC
5	cellular response to hypoxia	GO:0071456	9.97	MYC MIR17 MALAT1 BCL2
6	negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	GO:2001240	9.93	MCL1 BCL2L1 BCL2
7	extrinsic apoptotic signaling pathway in absence of ligand	GO:0097192	9.91	BCL2 BCL2L1 MCL1
8	negative regulation of dendritic cell apoptotic process	GO:2000669	9.88	BCL2L1 BCL2
9	T-helper 2 cell differentiation	GO:0045064	9.86	BCL6 BCL3
10	response to radiation	GO:0009314	9.8	PRDM1 BCL2L1 BCL2
11	response to fungus	GO:0009620	9.69	MALT1 BCL10
12	regulation of T cell receptor signaling pathway	GO:0050856	9.65	MALT1 BCL10
13	T cell apoptotic process	GO:0070231	9.63	BCL3 BCL2 BCL10
14	dendritic cell apoptotic process	GO:0097048	9.62	BCL2L1 BCL2
15	regulation of apoptotic process	GO:0042981	9.56	MCL1 MALT1 BCL3 BCL2L1 BCL2 BCL10
16	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.52	MIR20A MIR17
17	positive regulation of pulmonary blood vessel remodeling	GO:1905111	9.37	MIR20A MIR17
18	negative regulation of intrinsic apoptotic signaling pathway	GO:2001243	9.17	MIR17 MCL1 BCL2L1 BCL2

Molecular functions related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA-binding transcription factor binding	GO:0140297	9.76	MYC BCL6 BCL3 BCL2
2	kinase activator activity	GO:0019209	9.26	MALT1 BCL10
3	BH3 domain binding	GO:0051434	9.1	MCL1 BCL2L1 BCL2